PET/MRI Perfusion and CT Perfusion in Solid Tumors

University of Zurich43 enrolled

Overview

Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor physiology, diagnostic accuracy and possibly prognostic.

Study Type

OBSERVATIONAL

Enrollment

Conditions

CT Perfusion and MRI Perfusion in Solid Tumors

Eligibility

Sex: ALLMin age: 30 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * indication as stated above * written informed consent * patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT Exclusion Criteria: * pregnant or breast feeding women * non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia) * Inclusion in another clinical trial 30 days prior to inclusion * age \< 30years * contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia * known allergies to contrast CT or MRI contrast media * patients with an glomerular filtration rate of \< 60ml/min/1.73m2

Locations (1)

University Hospital Zurich, Diagnostic and Interventional Radiology

Zurich, Canton of Zurich, Switzerland

Outcomes

Primary Outcomes

Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.

Time frame: 18 months

Secondary Outcomes

Correlation of blood flow, blood volume and transfer constant (Ktrans) measured with CT-Perfusion and PET/MR-perfusion with progression free survival in solid tumors.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.